Immune Biosolutions Inc. news

Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug candidate maintains a potent activity in neutralization assays. Recent results have confirmed that this drug, IBIO123, is capable of neutralizing SARS-CoV-2 (COVID-19) and all its current variants of concern (VOCs) that have emerged throughout the pandemic, including the latest Omicron variant. IBIO123 is an inhaled antibody-based immunotherapy with an ongoing multisite phase 1 and 2 cl

Immune Biosolutions is pleased to announce the start of Phase I clinical trial for its immunotherapy (IBIO123) treatment, whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants. The treatment has the ability of being administered by inhalation and acts in a highly targeted manner through the lungs to fight the infection at its source.

This treatments aims to be complementary to vaccination and could be added to the tools used by health professionals,

Immune Biosolutions, an innovative biotechnology company, receives $13.44M from the Government of Canada’s Strategic Innovation Fund (SIF) to develop its promising immunotherapy whose antibodies have the potential to neutralize and eliminate COVID-19 and its variants.

This funding will allow the immunotherapy currently in pre-clinical studies to progress to Phase II clinical trials. In addition, Immune Biosolutions will build a biomanufacturing capacity to accelerate the pr

Immune Biosolutions, an early-stage biopharmaceutical company focusing on the discovery, engineering and development of therapeutic humanized chicken antibodies, today announced the appointments of Drs. Nadine Beauger and Louise Proulx to its Board of Directors.

Dr. Beauger is currently Chief Executive Officer at IRICoR—a drug discovery-focused Centre of Excellence in Commercialization and Research, based at Université de Montréal’s Institute for Research in

Immune Biosolutions Inc. (IBio), a JLABS @ Toronto resident company, today announced a research collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement, facilitated by Johnson & Johnson Innovation LLC, will focus initially on the discovery and development of therapeutic antibodies in oncology.

The collaboration will utilize IBio’s proprietary Nebula antibody discovery platform to adva

After winning a pitch competition earlier this year, Immune Biosolutions’ founders are participating this week in the Futurpreneur’s Growth Accelerator in Toronto. Immune Biosolutions was recognized among those with the greatest potential to impact the market in new ways. The founders are grateful to Futurpreneur, Spin Master, Morrison Financial and Dentons Canada for the invitation and look forward to creating useful connections that will foster the continued growth of

CQDM is pleased to announce the funding of a new $1.1 million research project in conjunction with financial contributions from lead industrial partner, Immune Biosolutions, and co-funding from:  Cancer Research Society, Mitacs, Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke and TransferTech. The funds will be used by the Université de Sherbrooke’s Professors Fernand Gobeil, Philippe Sarret and Fernand-Pierre Gendron and their respective teams to furth